Genmab — September 2017
-
Denne er da vist ny: Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT). This study evaluates the use of carfilzomib, lenalidomide, daratumumab, and dexamethasone in subjects with high-risk smoldering multiple myeloma (SMM).
-
-
Synes godt nok også, Genmab har været lidt kedelig i år

-
Nu må de kloge hoveder træde i karakter, det er længe siden vi har hørt fra dem. Der er kommet mange gode nyheder det sidste halve år, men ændrer ikke på at kursen ligger 3% lavere end for et halvt år siden. Men det tror da pokker, når alt det positive er indregnet i kursen !!!!!
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
